The BOD1 Knockout SK-HEP-1 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal population derived from the SK-HEP-1 human liver adenocarcinoma cell line, in which the BOD1 gene has been disrupted to create a loss-of-function model. This polyclonal format represents a heterogeneous pool of cells carrying diverse CRISPR/Cas9-mediated gene disruptions at the BOD1 locus, providing a genetically variable knockout population that avoids clonal selection artifacts. The product is designed for researchers investigating the molecular basis of chromosome segregation fidelity and its deregulation in cancer, particularly in the context of hepatocellular carcinoma. By ablating BOD1 function, the model enables detailed dissection of mitotic regulatory networks and the consequences of chromosomal instability in a physiologically relevant epithelial tumor background.
The parental SK-HEP-1 cell line was originally isolated from the ascitic fluid of a patient with liver adenocarcinoma and has become a widely employed model for hepatocellular carcinoma research. These cells exhibit an epithelial-like morphology combined with mesenchymal features, reflecting their origin from a metastatic site and making them particularly valuable for studies on tumor invasion, metastasis, and epithelial-mesenchymal transition. SK-HEP-1 cells are well-characterized in hepatic cancer biology, with documented genomic abnormalities and a propensity for anchorage-independent growth, and they are frequently utilized to evaluate the efficacy of chemotherapeutic agents and molecularly targeted therapies. Their robust growth in culture and suitability for genetic manipulation make them an ideal host for CRISPR/Cas9-mediated knockout studies aimed at uncovering tumor-suppressive or oncogenic pathways.
BOD1 (biorientation of chromosomes in cell division protein 1) encodes a kinetochore-associated factor essential for the faithful segregation of chromosomes during mitosis. Mechanistically, BOD1 recruits the PP2A holoenzyme, specifically the B56 regulatory subunit, to kinetochores, where it opposes Aurora B kinase-mediated phosphorylation of critical substrates such as the Ndc80 complex (HEC1). This balance between Aurora B and PP2A activities is fundamental for correcting erroneous kinetochore-microtubule attachments and establishing proper chromosome biorientation. BOD1 functions downstream of Aurora B and PP2A, interacting with the MIS12 complex and CENP-C, and its activity is regulated by cell cycle-dependent kinases like CDK1. Within the broader mitotic signaling network, BOD1 cooperates with components including PLK1, the KNL1?CMIS12?CNdc80 scaffold, and spindle assembly checkpoint proteins BUB1 and MAD2 to maintain genomic stability.
In the context of SK-HEP-1 cells, loss of BOD1 is expected to result in hyperactivation of Aurora B at kinetochores, leading to destabilized microtubule attachments, chromosome alignment defects, and a heightened rate of chromosome missegregation. Such mitotic errors are a hallmark of hepatocellular carcinoma, where chromosomal instability contributes to tumor heterogeneity, drug resistance, and metastatic progression. This knockout model thus provides a powerful tool to dissect the causal role of kinetochore signaling imbalances in liver cancer biology, offering insights into how defects in the PP2A?CAurora B regulatory axis fuel aneuploidy and shape the aggressive phenotype of SK-HEP-1 cells. By correlating BOD1 deficiency with altered cellular behaviors, researchers can explore mechanistic links between mitotic checkpoint dysfunction and the mesenchymal traits of this cell line.
Researchers can employ the BOD1 Knockout SK-HEP-1 Polyclonal Cells in a wide array of functional studies. Typical applications include assessing the fidelity of the spindle assembly checkpoint through immunofluorescence analysis of chromosome alignment and kinetochore markers, monitoring mitotic progression via live-cell imaging, and profiling cell cycle perturbations by flow cytometry. The model is also suited for screening small-molecule inhibitors targeting Aurora B or other mitotic kinases, evaluating clonogenic survival following drug treatment, and performing phospho-specific analysis of Aurora B substrates. In addition, downstream molecular phenotyping can be conducted using western blotting for BOD1, RNA-seq for global transcriptome responses, and drug sensitivity assays with microtubule poisons. For further details and custom inquiries, please contact Ascent Research.
